The Latest Breaking News from FDA

Juul just lost a big battle

The e-cigarette company was being investigated by more than 30 states for allegedly marketing its products to youth

Salon · Sep 9, 2022

3 Dividend Stocks You Can Buy and Hold for Years to Come

The stock market has witnessed significant volatility on worries over a slowing economy amid high inflation and the Fed’s hawkish stance to tame it. As these factors are expected to keep the market under pressure in the near term, it could be wise to invest in fundamentally strong dividend-paying stocks…

StockNews.com · Sep 9, 2022

Michael Hiltzik: This life-saving drug will cost a record $2.8 million. Who will pay the price?

For the estimated 1,500 Americans suffering from a blood disorder known as beta thalassemia, the Food and Drug Administration's approval Aug. 17 of the drug Zynteglo was almost unalloyed good news.

Los Angeles Times · Sep 9, 2022

Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.

Benzinga · Sep 9, 2022

Breast implants may be linked to more cancers than previously thought, FDA warns

‘This is an emerging issue and our understanding is evolving,’ FDA says

The Independent UK · Sep 9, 2022

Trump Ally Dr. Oz Hyped Unapproved 'Covid Cures' From Companies He Owns Shares Of

Republican Pennsylvania Senate candidate Dr. Mehmet Oz owns shares of two companies he publicly supported, touting their drugs as potential Covid-19 treatments — even though the drugs weren't approved by the U.S. Food and Drug Administration (FDA).

Benzinga · Sep 8, 2022

Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday

Gainers

Benzinga · Sep 8, 2022

Controversial ALS drug from Amylyx gets rare second FDA meeting

Amylyx Pharmaceuticals Inc.’s controversial treatment for amyotrophic lateral sclerosis won the support of a panel of U.S. regulatory advisers, putting the product on track for likely clearance.

Tribune News Service · Sep 7, 2022

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Benzinga · Sep 7, 2022

Potential to mix up omicron booster with conventional vaccine raises concerns

Experts are voicing concerns about the potential for vaccine providers to mix up the omicron booster vial with those used for conventional vaccines.

Los Angeles Times · Sep 7, 2022